34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pseudoprogression of brain tumors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This review describes the definition, incidence, clinical implications, and magnetic resonance imaging (MRI) findings of pseudoprogression of brain tumors, in particular, but not limited to, high‐grade glioma. Pseudoprogression is an important clinical problem after brain tumor treatment, interfering not only with day‐to‐day patient care but also the execution and interpretation of clinical trials. Radiologically, pseudoprogression is defined as a new or enlarging area(s) of contrast agent enhancement, in the absence of true tumor growth, which subsides or stabilizes without a change in therapy. The clinical definitions of pseudoprogression have been quite variable, which may explain some of the differences in reported incidences, which range from 9–30%. Conventional structural MRI is insufficient for distinguishing pseudoprogression from true progressive disease, and advanced imaging is needed to obtain higher levels of diagnostic certainty. Perfusion MRI is the most widely used imaging technique to diagnose pseudoprogression and has high reported diagnostic accuracy. Diagnostic performance of MR spectroscopy (MRS) appears to be somewhat higher, but MRS is less suitable for the routine and universal application in brain tumor follow‐up. The combination of MRS and diffusion‐weighted imaging and/or perfusion MRI seems to be particularly powerful, with diagnostic accuracy reaching up to or even greater than 90%. While diagnostic performance can be high with appropriate implementation and interpretation, even a combination of techniques, however, does not provide 100% accuracy. It should also be noted that most studies to date are small, heterogeneous, and retrospective in nature. Future improvements in diagnostic accuracy can be expected with harmonization of acquisition and postprocessing, quantitative MRI and computer‐aided diagnostic technology, and meticulous evaluation with clinical and pathological data.

          Level of Evidence: 3

          Technical Efficacy: Stage 2

          J. Magn. Reson. Imaging 2018;48:571–589.

          Related collections

          Most cited references117

          • Record: found
          • Abstract: found
          • Article: not found

          Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme.

          The objective of this study is to investigate the use of pattern classification methods for distinguishing different types of brain tumors, such as primary gliomas from metastases, and also for grading of gliomas. The availability of an automated computer analysis tool that is more objective than human readers can potentially lead to more reliable and reproducible brain tumor diagnostic procedures. A computer-assisted classification method combining conventional MRI and perfusion MRI is developed and used for differential diagnosis. The proposed scheme consists of several steps including region-of-interest definition, feature extraction, feature selection, and classification. The extracted features include tumor shape and intensity characteristics, as well as rotation invariant texture features. Feature subset selection is performed using support vector machines with recursive feature elimination. The method was applied on a population of 102 brain tumors histologically diagnosed as metastasis (24), meningiomas (4), gliomas World Health Organization grade II (22), gliomas World Health Organization grade III (18), and glioblastomas (34). The binary support vector machine classification accuracy, sensitivity, and specificity, assessed by leave-one-out cross-validation, were, respectively, 85%, 87%, and 79% for discrimination of metastases from gliomas and 88%, 85%, and 96% for discrimination of high-grade (grades III and IV) from low-grade (grade II) neoplasms. Multiclass classification was also performed via a one-vs-all voting scheme. (c) 2009 Wiley-Liss, Inc.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

            A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Improved survival time trends for glioblastoma using the SEER 17 population-based registries.

              The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received temozolomide with post-operative radiotherapy (RT). The current study was performed to determine if those results translated into a survival benefit in a population-based cohort. Patients diagnosed between 2000 and 2006 with a GBM who underwent surgery and post-operative RT were selected from the Surveillance, Epidemiology and End Results database. Patients were grouped into time periods: 2000-2001, 2002-2003, 2004 and 2005-2006 (which represented those treated after the EORTC/NCIC trial presentation in 2004). Relative survival (RS) was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios (HR). Over time, there was improvement in the median and 2-year RS of 12 months and 15% for 2000-2001, 13 months and 19% for 2002-2003, 14 months and 24% for 2004, and 15 months and 26% for 2005-2006 (P < 0.0001 compared to 2000-2001 and 2002-2003; P = 0.07 compared to 2004). The estimated adjusted HR showed that patients diagnosed in 2005-2006 had significantly improved survival when compared to patients diagnosed in 2000-2001 (HR = 0.648, 95% CI 0.604-0.696). The median and 2 year RS of 15 months and 26% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the current treatment of glioblastoma nationwide is now associated with an improved survival compared to previous time cohorts.
                Bookmark

                Author and article information

                Contributors
                marion.smits@erasmusmc.nl
                Journal
                J Magn Reson Imaging
                J Magn Reson Imaging
                10.1002/(ISSN)1522-2586
                JMRI
                Journal of Magnetic Resonance Imaging
                John Wiley and Sons Inc. (Hoboken )
                1053-1807
                1522-2586
                07 May 2018
                September 2018
                : 48
                : 3 ( doiID: 10.1002/jmri.v48.3 )
                : 571-589
                Affiliations
                [ 1 ] Lysholm Neuroradiology Department National Hospital for Neurology and Neurosurgery London UK
                [ 2 ] Department of Brain Rehabilitation and Repair UCL Institute of Neurology London UK
                [ 3 ] Imaging Department University College London Hospital London UK
                [ 4 ] Department of Neurology The Brain Tumor Centre at Erasmus MC Cancer Institute Rotterdam The Netherlands
                [ 5 ] Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Centre Rotterdam Rotterdam The Netherlands
                Author notes
                [*] [* ]Address reprint requests to: M.S., Department of Radiology and Nuclear Medicine (Hs‐220), Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands. E‐mail: marion.smits@ 123456erasmusmc.nl
                Article
                JMRI26171
                10.1002/jmri.26171
                6175399
                29734497
                93f7feca-e1a6-4c67-a1b5-74c49aed5f7a
                © 2018 The Authors Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 04 February 2018
                : 07 April 2018
                Page count
                Figures: 12, Tables: 1, Pages: 19, Words: 11358
                Funding
                Funded by: University College London NIHR Biomedical Research Centre
                Categories
                CME Article
                CME Article
                Custom metadata
                2.0
                jmri26171
                September 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.0 mode:remove_FC converted:08.10.2018

                Radiology & Imaging
                glioma,mri,perfusion weighted,proton magnetic resonance spectroscopy,brain neoplasms,magnetic resonance imaging,diffusion

                Comments

                Comment on this article